analysis indicated accelerated anaerobic glycolysis and nucleotide degradation and suppressed TCA cycle and fatty acid biosynthesis in the PDAC lesions.

Supplementary material

Supplementary Table 1 and Figure 1 can be found at http://carcin. oxfordjournals.org/

References

1. Jemal,A. *et al.* (2003) Cancer statistics, 2003. *CA Cancer J. Clin.*, **53**, 5–26.
2. Akdogan,M. *et al.* (2001) Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. *Tumori*, **87**, 337–339.
3. Ni,X.G. *et al.* (2005) The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. *Eur. J. Surg. Oncol.*, **31**, 164–169.
4. Duffy,M.J. (1998) CA 19-9 as a marker for gastrointestinal cancers: a review. *Ann. Clin. Biochem.*, **35** (Pt 3), 364–370.
5. Ueda,S. *et al.* (2006) Ductal origin of pancreatic adenocarcinomas induced by conditional activation of a human Ha-ras oncogene in rat pancreas. *Carcinogenesis*, **27**, 2497–2510.
6. Fiehn,O. (2002) Metabolomics—the link between genotypes and phenotypes. *Plant Mol. Biol.*, **48**, 155–171.
7. Nicholson,J.K. *et al.* (1999) 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. *Xenobiotica*, **29**, 1181–1189.
8. Beckonert,O. *et al.* (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. *Nat. Protoc.*, **2**, 2692–2703.
9. Dettmer,K. *et al.* (2007) Mass spectrometry-based metabolomics. *Mass Spectrom. Rev.*, **26**, 51–78.
10. Weckwerth,W. *et al.* (2005) Metabolomics: from pattern recognition to biological interpretation. *Drug Discov. Today*, **10**, 1551–1558.
11. Sreekumar,A. *et al.* (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. *Nature*, **457**, 910–914.
12. Tanaka,H. *et al.* (2010) Mature acinar cells are refractory to carcinoma development by targeted activation of Ras oncogene in adult rats. *Cancer Sci.*, **101**, 341–346.
13. Fukamachi,K. *et al.* (2009) An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas. *Biochem. Biophys. Res. Commun.*, **390**, 636–641.
14. Garber,K. (2004) Energy boost: the Warburg effect returns in a new theory of cancer. *J. Natl Cancer Inst.*, **96**, 1805–1806.
15. Warburg,O. (1956) On the origin of cancer cells. *Science*, **123**, 309–314.
16. Menendez,J.A. *et al.* (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nat. Rev. Cancer*, **7**, 763–777.
17. Tiziani,S. *et al.* (2009) Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. *Neoplasia*, **11**, 269–276, 4p following 269.
18. Hirayama,A. *et al.* (2009) Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. *Cancer Res.*, **69**, 4918–4925.
19. Nishiumi,S. *et al.* (2010) Serum metabolomics as a novel diagnostic approach for pancreatic cancer. *Metabolomics*, **6**, 518–528.
20. Urayama,S. *et al.* (2010) Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. *Rapid Commun. Mass Spectrom.*, **24**, 613–620.